AGP Executive Report
Last update: 2 hours agoCancer Drug Deal: HUTCHMED’s shares jumped after it licensed its first-in-class KRAS-EGFR antibody-targeted therapy HMPL-A830 to GSK for a $110M upfront payment, with up to about $1.3B in milestones and royalties; GSK will run later trials and commercialization outside Mainland China, Hong Kong, Macao and Taiwan, while Phase I is set to start in H2 2026. Public Health Logistics: Macao is piloting drone deliveries for medical samples between Conde de São Januário Hospital and the Macao Medical Center of Peking Union Medical College Hospital, aiming for 10–15 minutes but noting hurdles like dense airspace restrictions and standards. School Safety: Police reported an 18-year-old student in Macao allegedly splashed a teacher with drain cleaner, causing burns; both were treated at Conde de São Januário Hospital Centre and the case is being followed up by the Judiciary Police. Healthcare Industry & TCM: HEC Group announced strategic partnerships in Macao to strengthen production and international development of its Cordyceps sinensis health product line, aligning with the city’s “1+4” diversification and big health push. Wellness & Food Retail: Wellcome in Hong Kong (with links to Macau via DFI Retail Group) partnered with CJ Foods to expand Korean product offerings, targeting over $22M in sales, including “healthy meals.”
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
